Pharma Trend Outlook 2022

It was reported that over 79,000 people died of flu in the U.S. in the winter of 2017-2018, which was the highest death toll in four decades.1 It seems like the 2018-2019 flu season isn’t so bad. How are sales of OTC drugs impacted by the severity of flu seasons? Are there any opportunities for new products to capture market share? How can companies ensure reliable supply of OTC medications based upon expected spikes in demand?

In this on-demand webinar, discover the differences between FTIR, NIR and Raman spectroscopy, learn how spectroscopy is applied in quality control labs and hear how implementation of these techniques increased efficiency and minimised costs.

After years of innovative research, advanced therapies are dramatically changing the way patients are treated for a wide variety of diseases particularly for patients with rare diseases and orphan indications. New developments in advanced therapy medicinal products (ATMPs) comprising cell and gene therapy products show the potential to modify or even cure severe chronic conditions for which previously no treatment existed. As a consequence, the dynamic market for innovative therapies such as CAR-T, immuno-oncology, and gene and cell-based therapies grows across the globe. Academic institutes and biotech companies are contributing to these developments both in terms of scientific discovery and undertaking clinical trials aiming for regulatory approvals to treat specific patient populations. While we might be in a golden age of medicine due to advancements in ATMPs, innovative clinical research and development remain crucial for getting treatments to patients.

In this on-demand webinar, we discuss the key takeaways of the proposed rule, including its potential impact, if finalized, on various stakeholders, including PBMs, health plans, drug manufacturers, and pharmacies.